Format
Sort by

Send to

Choose Destination

Search results

Items: 14

1.

Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries.

Davila-Seijo P, Garcia-Doval I, Naldi L, Cazzaniga S, Augustin M, Rustenbach SJ, Daudén E, Dam TN, Baker C, Spuls PI, Stern RS, Cohen AD.

Acta Derm Venereol. 2016 Nov 24. doi: 10.2340/00015555-2586. [Epub ahead of print]

2.

Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis.

Dávila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García FJ, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Torrado R, Carrascosa JM, Llamas M, Rivera R, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group..

J Eur Acad Dermatol Venereol. 2016 Nov;30(11):1942-1950. doi: 10.1111/jdv.13682.

PMID:
27329511
3.

Drug Survival Analysis Is Not a Good Method for Assessing the Safety or Effectiveness of Systemic Therapies in Psoriasis.

Dávila-Seijo P, García-Doval I.

Actas Dermosifiliogr. 2017 Jan - Feb;108(1):3-5. doi: 10.1016/j.ad.2016.09.001. English, Spanish. No abstract available.

PMID:
27765164
4.

Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry.

Dávila-Seijo P, Dauden E, Descalzo MA, Carretero G, Carrascosa JM, Vanaclocha F, Gómez-García FJ, De la Cueva-Dobao P, Herrera-Ceballos E, Belinchón I, López-Estebaranz JL, Alsina M, Sánchez-Carazo JL, Ferrán M, Torrado R, Ferrandiz C, Rivera R, Llamas M, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group..

J Invest Dermatol. 2016 Sep 25. pii: S0022-202X(16)32459-9. doi: 10.1016/j.jid.2016.08.034. [Epub ahead of print]

PMID:
27677836
5.

Prioritization of therapy uncertainties in congenital ichthyosis: results from a Priority Setting Partnership.

Hernández-Martín A, Dávila-Seijo P, de Lucas R, Baselga E, Redondo P, Martín-Santiago A, Azaña-Defez JM, González-Viejo I, Jiménez-Ferreres L, González-Enseñat MA, Arroyo-Manzanal MI, Soria JM, Garcia-Doval I.

Br J Dermatol. 2015 Nov;173(5):1280-3. doi: 10.1111/bjd.13914. No abstract available.

PMID:
25996448
6.

LEOPARD syndrome without hearing loss or pulmonary stenosis: a report of 2 cases.

Ramos-Geldres TT, Dávila-Seijo P, Duat-Rodríguez A, Noguera-Morel L, Ezquieta-Zubicaray B, Rosón-López E, Hernández-Martín A, Torrelo-Fernández A.

Actas Dermosifiliogr. 2015 May;106(4):e19-22. doi: 10.1016/j.ad.2014.11.004. English, Spanish.

PMID:
25544017
7.

Current dystrophic epidermolysis bullosa research does not match research needs perceived by patients and clinicians.

Davila-Seijo P, Hernández-Martín Á, Morcillo-Makow E, Rajan C, García-Doval I.

J Am Acad Dermatol. 2014 Nov;71(5):1008-11. doi: 10.1016/j.jaad.2014.05.038. No abstract available.

PMID:
25437964
8.

Autoinflammatory syndromes for the dermatologist.

Dávila-Seijo P, Hernández-Martín A, Torrelo A.

Clin Dermatol. 2014 Jul-Aug;32(4):488-501. doi: 10.1016/j.clindermatol.2014.02.004. Review.

PMID:
25017460
9.

The use of systematic reviews in clinical trials and narrative reviews in dermatology: is the best evidence being used?

Conde-Taboada A, Aranegui B, García-Doval I, Dávila-Seijo P, González-Castro U.

Actas Dermosifiliogr. 2014 Apr;105(3):295-9. doi: 10.1016/j.adengl.2013.10.007.

PMID:
24661956
10.

Topical N-acetylcysteine for the treatment of lamellar ichthyosis: an improved formula.

Davila-Seijo P, Flórez A, Davila-Pousa C, No N, Ferreira C, De la Torre C.

Pediatr Dermatol. 2014 May-Jun;31(3):395-7. doi: 10.1111/pde.12305.

PMID:
24602057
11.

Spontaneous partial repigmentation of halo nevi around congenital melanocytic nevus and vitiligo in a 13-year-old boy.

Concha-Garzón MJ, Hernández-Martín A, Faura-Berruga C, Dávila-Seijo P, Torrelo A.

Indian J Dermatol Venereol Leprol. 2014 Jan-Feb;80(1):69-70. doi: 10.4103/0378-6323.125539. No abstract available.

12.

Usefulness of Cochrane Skin Group reviews for clinical practice.

Davila-Seijo P, Batalla A, Garcia-Doval I.

Actas Dermosifiliogr. 2013 Oct;104(8):679-84. doi: 10.1016/j.adengl.2012.12.009.

PMID:
23954044
13.

Prioritization of therapy uncertainties in Dystrophic Epidermolysis Bullosa: where should research direct to? an example of priority setting partnership in very rare disorders.

Davila-Seijo P, Hernández-Martín A, Morcillo-Makow E, de Lucas R, Domínguez E, Romero N, Monrós E, Feito M, Carretero L, Aranegui B, García-Doval I.

Orphanet J Rare Dis. 2013 Apr 22;8:61. doi: 10.1186/1750-1172-8-61.

14.

Updated systematic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosa.

Garcia-Doval I, Davila-Seijo P, Langan SM.

Clin Exp Dermatol. 2013 Jan;38(1):92-4. doi: 10.1111/j.1365-2230.2012.04419.x. Review. No abstract available.

PMID:
22731863
Items per page

Supplemental Content

Loading ...
Support Center